|
Safety and Effectiveness of Zemplar Injection in decreasing iPTH levels in pediatric ESRD subjects on hemodialysis Clinical Trials Data presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, calls or treatment using a genuine doctor. We are not docs. Always consult your dr. on Safety and Effectiveness of Zemplar Injection in decreasing iPTH levels in pediatric ESRD subjects on hemodialysis conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Safety and Effectiveness of Zemplar Injection in decreasing iPTH levels in pediatric ESRD subjects on hemodialysis Clinical research trials and Safety and Effectiveness of Zemplar Injection in decreasing iPTH levels in pediatric ESRD subjects on hemodialysis healthcare trials occur in a lot of of places throughout the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the potency of new drugs. The intent of the studies / undertakings is to figure out certain human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector corporations to locate remedies for all kinds of circumstances, including Safety and Effectiveness of Zemplar Injection in decreasing iPTH levels in pediatric ESRD subjects on hemodialysis. Safety and Effectiveness of Zemplar Injection in decreasing iPTH levels in pediatric ESRD subjects on hemodialysis Clinical Trials and other clinical trials allow volunteers to obtain health treatment alternatives before they are available to the masses. Many times the participants undergo treatment for free, and sometimes they are paid for their time. Occasionally there is a cost for a Safety and Effectiveness of Zemplar Injection in decreasing iPTH levels in pediatric ESRD subjects on hemodialysis clinical trial. Participants typically obtain the most effective healthcare available for their Safety and Effectiveness of Zemplar Injection in decreasing iPTH levels in pediatric ESRD subjects on hemodialysis condition. Dangers are a reality, nonetheless, and can include extra or frequent mD trips, medical hazards (potentially life-endangering), and/or the treatment being uneffective. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Safety and Effectiveness of Zemplar Injection in decreasing iPTH levels in pediatric ESRD subjects on hemodialysis Safety and Effectiveness of Zemplar Injection in decreasing iPTH levels in pediatric ESRD subjects on hemodialysis
Safety and Effectiveness of Zemplar Injection in decreasing iPTH levels in pediatric ESRD subjects on hemodialysis
For Condition: End Stage Renal Disease,Secondary Hyperparathyroidism
Status: Completed
Sponsor(s): Abbott Laboratories ,
Synopsis: The purpose of this study is to see if Zemplar, a vitamin D medication, safely and effectively decreases parathyroid hormone in children ages 2-20 with End Stage Renal Disease.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Safety/Efficacy Study
Minimum Age/Maximum Age: 2 Years/20 Years
Genders: Both
Protocol Entry Criteria: Subjects ages 2-20 with ESRD on hemodialysis with Secondary hyperparathyroidism
Total Enrollment: 28
Location and Contact Information:
Overall Study Official:
DheerendraKommala, , Abbott Laboratories
Miami Children's Hospital
Miami, Florida,
United States
The Children's Hospital of Buffalo
Buffalo, New York,
United States
Texas Children's Hospital
Houston, Texas,
United States
Stanford University Medical Center
Stanford, California, 94305
United States
Medical College of Wisconsin
Milwaukee, Wisconsin,
United States
University of Texas at Houston
Houston, Texas,
United States
Additional Information:
Study ID Numbers: 2001-022;
Study Start Date: January 2002
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00053547
Other Secondary Hyperparathyroidism Studies:
1. Phase II Randomized Study of the Effects of Growth Hormone on Children and Adolescents on Maintenance Dialysis
2. Homocysteine Study (HOST)
3. Randomized Study of Folic Acid Therapy for Hyperhomocysteinemia in Patients with End Stage Renal Disease Receiving Hemodialysis
4. Phase II Randomized Study of Standard vs High Amount of Hemodialysis Using Low vs High Flux Dialyzer Membranes for End Stage Renal Disease
5. A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients
Related Studies:
Other Secondary Hyperparathyroidism Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials
Safety and Effectiveness of Zemplar Injection in decreasing iPTH levels in pediatric ESRD subjects on hemodialysis
|
|
|
|
|
|
|
|